

Apalutamide SPARTAN

PRELIMINARY SCORE

CURATIVE



NON-CURATIVE



ADJUSTMENTS

Quality of life



Serious and disabling adverse effects



Other adjustments



Apalutamide SPARTAN

SCORE

CURATIVE




Overall Survival / Disease-Free Survival / Pathological Complete Response

NON-CURATIVE




Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Tumour type: Genitourinary Cancers  
 Therapeutic Indication: Treatment of non metastatic castration resistant prostate cancer (nmCRPC) in adult men who are at high risk of developing metastatic disease  
 Experimental Arm: Apalutamide + ADT (androgen deprivation therapy)  
 Control Arm: ADT + placebo

